[ad_1]
Synopsis
Thakur rose to prominence as the whistleblower who busted data fabrication and other misdeeds of Ranbaxy for its supplies in the US. In a no-holds-barred conversation, he explains the objectives of his relentless campaign to clean up the system and how he is building a body of evidence that could someday make India’s public-health system more robust.
His name splits the Indian drug industry down the middle. Dinesh Thakur is either admired for his tireless zeal to bring about reform in India’s drug-regulatory system, or tempers flare up at the mention of his name. His motives are often questioned for chasing an “agenda” to malign drugmakers of India, which prides itself on being the pharmacy of the world. But a closer look reveals the merit in his assertions. Thakur has studied India’s
BY
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal Ads
Comment & Engage with ET Prime community 
Exclusive invites to Virtual Events with Industry Leaders 
A trusted team of Journalists & Analysts who can best filter signal from noise
[ad_2]
Source link
